Prognostic significance of MYCN oncogene expression in childhood neuroblastoma

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3286-3294

  Bordow, Sharon B ^a   Norris, Murray D ^a   Haber, Paul S ^a   Marshall, Glenn M ^a   Haber, Michelle ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CANCER STAGING; CHILD; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; NEUROBLASTOMA; ONCOGENE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 0031727309     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3286     Document Type: Article

References (59)

1. Brodeur GM, Castleberry RP: Neuroblastoma, in Pizzo AP, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 2). Philadelphia, PA, Lippincott, 1993, pp 737-739
2. proto-trk is expressed in neuroblastoma of patients with good prognosis. Jpn J Cancer Res 85:32-39, 1994
3. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993
4. Favrot MC, Ambros P, Schilling F, et al: Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Ann Oncol 7:607-611, 1996
5. Chung HS, Higgins GR, Siegel SE, et al: Abnormalities of the immune system in children with neuroblastoma related to the neoplasm and chemotherapy. J Pediatr 90:548-554, 1977
6. Cassady JR: A hypothesis to explain the enigmatic natural history of neuroblastoma. Med Pediatr Oncol 12:64-67, 1984
7. Carlsen NLT: Why age has independent prognostic significance in neuroblastomas. Evidence for intra-uterine development, and implications for the treatment of the disease. Anticancer Res 8:255-262, 1988
8. Brodeur GM: Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 31:505-510, 1995
9. Combaret V, Gross N, Lasset C, et al: Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14:25-34, 1996
10. Norris MD, Bordow SB, Marshall GM, et al: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231-238, 1996
11. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
12. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 313:1111-1116, 1985
13. Brodeur GM, Fong CT: Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41:153-174, 1989
14. Look AT, Hayes FA, Shuster JJ, et al : Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991
15. Tonini GP, Boni L, Pession A, et al: MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian experience with 295 children. J Clin Oncol 15:85-93, 1997
16. Lutz W, Stohr M, Schurmann J, et al: Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13:803-812, 1996
17. Schweigerer L, Breit S, Wenzel A, et al: Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: Evidence for induction of autocrine growth factor activity. Cancer Res 50:4411-4416, 1990
18. Gross N, Miescher G, Beck D, et al: Altered growth and phenotype in clonal MYCN transfectants of the SK-N-SH neuroblastoma cell line. Int J Cancer 59:141-148, 1994
19. Negroni A, Scarpa S, Romeo A, et al: Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Diff 2:511-518, 1991
20. Whitesell L, Rosolen A, Neckers LM: Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuro-ectodermal cell lines. Mol Cell Biol 11:1360-1371, 1991
21. Weiss WA, Aldape K, Mohapatra G, et al: Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16:2985-2995, 1997
22. Seeger RC, Wada R, Brodeur GM, et al: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49, 1988
23. Nisen PD, Waber PG, Rich MA, et al: N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 80:1633-1637, 1988
24. Slave I, Ellenbogen R, Jung W-H, et al: myc Gene amplification and expression in primary human neuroblastoma. Cancer Res 50:1459-1463, 1990
25. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 27:374-378. 1971
26. Nitschke R, Smith EI, Shochat S, et al: Localized neuroblastoma treated by surgery: A Pediatric Oncology Group Study. J Clin Oncol 6:1271-1279, 1988
27. Telford DJ, Kavallaris M, White L, et al: Association of N-myc amplification with neuroblastoma: The Australian and New Zealand experience. J Paediatr Child Health 28:58-63, 1992
28. Bordow SB, Haber M, Madafiglio J, et al: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54:5036-5040, 1994
29. Noonan KE, Beck C, HolzmayerTA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87:7160-7164, 1990
30. Holzmayer TA, Hilsenbeck S, Von Hoff DD, et al: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84:1486-1491, 1992
31. Kavallaris M, Kuo DYS, Burkhart CA, et al: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100:1282-1293, 1997
32. Marshall GM, Cheung B, Stacey KP, et al. Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. Oncogene 11:485-491, 1995
33. Morris JA, Gardner MJ: Calculating confidence intervals for relative risks, odds ratios, and standardised ratios and rates, in Gardner MJ, Altman DG (eds): Statistics With Confidence: Confidence Intervals and Statistical Guidelines. London, England, British Medical Journal, 1989, pp 50-63
34. Jaffe N: Neuroblastoma: Review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat Rev 3:61-82, 1976
35. Breslow N, McCann B: Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31:2098-2103, 1971
36. Bartram CR, Berthold F: Amplification and expression of the N-myc gene in neuroblastoma. Eur J Pediatr 146:162-165, 1987
37. Grady-Leopardi EF, Schwab M, Ablin AR, et al: Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: Relationship to clinical outcome. Cancer Res 46:3196-3199, 1986
38. Hiyama E, Hiyama K, Yokoyama T, et al: Immunohistochemical analysis of N-myc protein expression in neuroblastoma: Correlation with prognosis of patients. J Pediatr Surg 26:838-843, 1991
39. Chan HSL, Gallie BL, Deboer G, et al: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3:1699-1706, 1997
40. Versteeg R, van der Minne C, Plomp A, et al: N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol 10:5416-5423, 1990
41. Cheng NC, Van Roy N, Chan A, et al: Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene 10:291-297, 1995
42. Nakagawara A, Kadomatsu K, Sato S-I, et al: Inverse correlation between expression of multidrug resistance gene and N-myr oncogene in human neuroblastomas. Cancer Res 50:3043-3047, 1990
43. Nakada K, Fujioka T, Kitagawa H, et al: Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis. Jpn J Clin Oncol 23:149-155, 1993
44. Matsunaga T, Takahashi H, Ohnuma N, et al: Expression of N-myc and c-src proto-oncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. Cancer Res 51:3148-3152, 1991
45. Nakagawara A, Sasazuki T, Akiyama H, et al: N-myc oncogene and stage IV-S neuroblastoma. Cancer 65:1960-1967, 1990
46. Nakagawara A, Arima M, Azar CG, et al: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52:1364-1368, 1992
47. Woods WG, Lemieux B, Tuchman M: Neuroblastoma represents distinct clinical-biologic entities: A review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 89:114-118, 1992
48. Nakagawara A, Zaizen Y, Ikeda K, et al: Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 68:2037-2044, 1991
49. Takeuchi LA, Hachitanda Y, Woods WG, et al: Screening for neuroblastoma in North America: Preliminary results of a pathology review from the Quebec project. Cancer 76:2363-2371, 1995
50. Brodeur GM: Neuroblastoma: Clinical significance of genetic abnormalities. Cancer Surv 9:673-688, 1990
51. Paul SR, Tarbell NJ, Korf B, et al: Stage IV neuroblastoma in infants: Long-term survival. Cancer 67:1493-1497, 1991
52. Kusafuka T, Nagahara N, Oue T, et al: Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastoma detected through mass screening. Cancer 76:695-699, 1995
53. Castleberry RP, Shuster JJ, Altshuler G, et al: Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: A Pediatric Oncology Group study. J Clin Oncol 10:1299-1304, 1992
54. De Bernardi B, Pianca C, Boni L, et al: Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Cancer 70:1625-1633, 1992
55. Cohn SL, Look AT, Joshi VV, et al: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study. Cancer Res 55:721-726, 1995
56. Hashimoto H, Daimaru Y, Enjoji M, et al: N-myc gene product expression in neuroblastoma. J Clin Pathol 42:52-55, 1989
57. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85:377-384, 1993
58. Garvin J Jr, Bendit I, Nisen PD: N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma. Cancer 65:2572-2575, 1990
59. Gazitt Y, He YJ, Chang L, et al: Expression of N-myc, c-myc, and MDR-1 proteins in newly established neuroblastoma cell lines: A study by immunofluorescence staining and flow cytometry. Cancer Res 52: 2957-2965, 1992